Isotechnika Presents Positive Data From the Promise Trial of Voclosporin at the American Transplant Congress

Isotechnika Inc. announces the successful results of the Phase 2b PROMISE trial which were presented by Dr. A. Osama Gaber, an investigator for the PROMISE trial, at the 2008 American Transplant Congress in Toronto, Canada. The presentation detailed the final data confirming the efficacy of Isotechnika's next generation calcineurin inhibitor, voclosporin (ISA247), in de novo kidney transplant patients. An improved safety profile versus tacrolimus was also reported. Dr. Gaber is the Director of Transplantation, Vice-Chair for Administration and Faculty Affairs, Department of Surgery, The Methodist Hospital (Houston) and Cornell University (New York).

"Despite the...

Want to see the full article?

• Purchase this article for only $3.00